2. Antibody-drug Conjugate/ADC Related Apoptosis
  3. Antibody-Drug Conjugates (ADCs) Apoptosis TNF Receptor
  4. Brentuximab vedotin

Brentuximab vedotin  (Synonyms: 维布妥昔单抗；本妥昔单抗)

目录号: HY-P99107 纯度: 98.00%
COA 产品使用指南

摩尔计算器

Brentuximab vedotin (cAC10-vcMMAE) 是一种抗体-活性分子偶联物 (ADC)，由抗 CD30 抗体和 Monomethyl auristatin E (MMAE) 组成。Brentuximab vedotin 抑制 CD30 阳性细胞，其 IC50 值为 2.5 ng/mL。Brentuximab vedotin 可用于复发难治性霍奇金淋巴瘤的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Brentuximab vedotin Chemical Structure

Brentuximab vedotin Chemical Structure

CAS No. : 914088-09-8

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥5000
In-stock
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Brentuximab vedotin:

Brentuximab vedotin 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2].

IC50 & Target

IC50: 2.5 ng/mL (CD30)[2]
体外研究
(In Vitro)

Brentuximab vedotin (cAC10-vcMMAE) (1 μg/mL；96 h) 在 Karpas 299 细胞中显示出对 CD30+ 的细胞毒性[2]。
Brentuximab vedotin (CAC10-VCMMAE) (1 μg/mL；12，24 和 48 h) 选择性诱导 G2/M 期生长停滞，然后导致细胞凋亡[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Brentuximab vedotin 相关抗体:

Cell Cytotoxicity Assay[2]

Cell Line: Karpas 299 cells
Concentration: 1 μg/mL
Incubation Time: 96 h
Result: Showed cytotoxicity to CD30+ Karpas 299 cells with an IC50 value of 2.5 ng/mL.

Cell Cycle Analysis[2]

Cell Line: L540 cells
Concentration: 1 μg/mL
Incubation Time: 12, 24, and 48 h
Result: Selectively induced growth arrest in G2/M phase to apoptotic cell death.
体内研究
(In Vivo)

Brentuximab vedotin (cAC10-vcMMAE) (10-120 mg/kg；腹腔注射 3 周) 最大耐受剂量 (MTD) 在 30 和 40 mg/kg 之间[2]。
Brentuximab vedotin (cAC10-vcMMAE) (0.3、1 mg/kg；侧腹注射；每 4 天一次，总共 4 剂 1 mg/kg) 诱导肿瘤 CD30 消退[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID mice[2]
Dosage: 10 to 120 mg/kg
Administration: Intravenous injection; 10 to 120 mg/kg; for 3 weeks
Result: Showed an maximum tolerated dose between 30 and 40 mg/kg.
Animal Model: SCID mice[2]
Dosage: 0.3 and 1 mg/kg
Administration: Flanks injection; 1 mg/kg every 4 days for a total of 4 doses; 0.3 mg/kg every 4 days for a total of 4 doses
Result: Induced complete and durable tumor regression, but 0.3 mg/kg provided lower therapy than 1 mg/kg dose.
Clinical Trial
CAS 号
性状

固体

颜色

White to off-white

中文名称

维布妥昔单抗；本妥昔单抗
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

纯度 & 产品资料

纯度: 98.00%

COA (242 KB)

产品使用指南 (1538 KB)
参考文献

Brentuximab vedotin 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Brentuximab vedotin914088-09-8维布妥昔单抗本妥昔单抗Antibody-Drug Conjugates (ADCs)ApoptosisTNF ReceptorAntibody-Drug ConjugatesTumor Necrosis Factor ReceptorTNFRcAC10-vcMMAESGN-35antibody-drug conjugateT-cell lymphomacutaneous T-cell lymphomaInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Brentuximab vedotin
目录号：
HY-P99107
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z